Formuepleje A/S’s Alexion Pharmaceuticals ALXN Stock Holding History

Formuepleje A/S’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-11,721	Closed	-$2.15M	–	101
2021 Q2	$2.15M	Sell	11,721 -13,103	-53%	-$2.25M	0.08%	63
2021 Q1	$3.8M	Sell	24,824 -3,499	-12%	-$541K	0.14%	59
2020 Q4	$4.43M	Sell	28,323 -5,759	-17%	-$740K	0.19%	52
2020 Q3	$3.9M	Buy	34,082 +4,193	+14%	+$452K	0.17%	53
2020 Q2	$3.35M	Sell	29,889 -4,035	-12%	-$428K	0.17%	55
2020 Q1	$3.05M	Buy	33,924 +15,851	+88%	+$1.56M	0.2%	54
2019 Q4	$1.95M	Buy	18,073 +6,395	+55%	+$684K	0.13%	47
2019 Q3	$1.14M	Buy	+11,678	New	+$1.32M	0.08%	53

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Formuepleje A/S's ALXN Position: Q3 2021 in Review

Formuepleje A/S sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 11,721 shares — an estimated $2.15M sold.

Formuepleje A/S first reported a position in ALXN in Q3 2019 and held it in 8 quarters. The position peaked at $4.43M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Formuepleje A/S reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Formuepleje A/S sold 11,721 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2.15M.
Formuepleje A/S first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 8 quarters.
Formuepleje A/S's Alexion Pharmaceuticals position peaked at $4.43M in Q4 2020.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Formuepleje A/S's 13F filing for Q3 2021, filed 27 Aug 2026.